Endo completes tender offer for Indevus
Executive Summary
Endo completes tender offer for outstanding shares of Indevus Pharmaceuticals common stock via subsidiary BTB Purchaser Inc., the firm announces March 19. More than 70 million (nearly 89 percent) of Indevus' outstanding shares were "validly tendered" at the close of business March 18. Endo also is effecting a short-form merger between BTB and Indevus (with Indevus continuing as a wholly owned subsidiary of Endo) to complete the acquisition of 100 percent of Indevus' common stock